Overcoming obstacles in Parkinson's disease

Movement Disorders

Volumn 27, Issue 13, 2012, Pages 1606-1611

  Sherer, Todd B ^a   Chowdhury, Sohini ^a   Peabody, Katherine ^a   Brooks, Deborah W ^a  

^a THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

Alpha synuclein; Biomarkers; Clinical trial recruitment; Disease modification

Indexed keywords

ADENOSINE; ALPHA SYNUCLEIN; GLUTAMIC ACID; RASAGILINE; SEROTONIN;

COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE COURSE; DYSKINESIA; GENE MUTATION; HEALTH CARE COST; HUMAN; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; STANDARDIZATION;

CLINICAL TRIALS AS TOPIC; HUMANS; PARKINSON DISEASE;

EID: 84870340462     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25260     Document Type: Review

References (42)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, et al Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022.
2. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-596.
3. Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Trans Suppl 2006; 76: 99-103.
4. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53 (Suppl 3): S3-S12.
5. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson's disease: an expert consensus and review of key issues. Arch Neurol 2010; 68: 165.
6. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
7. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the parkin gene in affected individuals. Ann Neurol 1998; 44: 935-941.
8. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Gen 1998; 18: 106-108.
9. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
10. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
11. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK 8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
12. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
13. Zimprich A, Biskup S, Letner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
14. Sidransky E, Nalls M, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Eng J Med 2009; 361: 907-914.
15. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Gen 2009; 41: 1308-1312.
16. Gorell JM, Rybicki BA, Johnson CC, et al. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52: 115-119.
17. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal anti-inflammatory drug use and the risk of Parkinson's disease. Ann Neurol 2005; 58: 963-967.
18. Munoz A, Carlsson T, Tronci E, et al. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5HT1A and 5HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009; 219: 298-307.
19. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind randomized trial. Lancet Neurol 2011; 10: 221-229.
20. Jones CK, Bubser M, Thompson AD, et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther 2012; 340: 404-421.
21. Goetz CG, Emre M, and Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008; 64 (Suppl 2): S81-S92.
22. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord 2010; 25: 1131-1142.
23. Richard IH, McDermott MP, Kurlan RM, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in PD. Neurology 2012; 78: 1229-1236.
24. McCormack AL, Mak SK, Henderson JM, et al. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 2010; 5: e12122.
25. Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci 2011; 31: 6963-6971.
26. Anand VS, Reichling LJ, Lipinski K, et al. Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 2009; 276: 466-478.
27. Nichols RJ, Dzamko N, Hutti JE, et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 2009; 424: 47-60.
28. Herzig MC, Kolly C, Persohn E, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 2011; 20: 4209-4223.
29. Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Parkinson's disease. Parkinsonism Relat Disod 2012; 18 (Suppl 1): S183-S185.
30. Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010; 25: 1774-1779.
31. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New Eng J Med 2009; 361: 1268-1278.
32. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson's disease: using futility designs. Neurology 2006; 66: 628-633.
33. Parkinsion Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-635.
34. Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012; 27: 406-412.
35. Alcalay RM, Mejia-Santana H, Tang MX, et al. Motor phenotype of LRRK2 G2019S carriers in early-onset PD. Arch Neurol 2009; 66: 1517-1522.
36. Kost RG, Lee LM, Yesis J, et al. Assessing research participants perceptions of their clinical research experience. Clin Trans Sci 2011; 4: 403-411.
37. DiMasi JA, Hansen R, Grabowski HG, et al. The price of innovation: new estimates of drug development costs. J Health Econom 2003; 22: 141-185.
38. Lovato LC, Hill K, Hertert S, et al. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Controlled Clin Trials 1997; 18: 328-357.
39. Valadas A, Coelho M, Mestre T, et al. What motivates Parkinson's disease patients to enter clinical trials? Parkinsonism Relat Disord 2011; 17: 667-671.
40. Mainous IIIAG, Smith DW, Geesey ME, et al. Factors influencing physician referrals of patients to clinical trials. J Nat Med Assoc 2008; 100: 1298-1303.
41. LeWitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson's disease (FJORD STUDY). Neurology 2012; 79: 163-169.
42. Kaitin KI, ed. Pace of CNS drug development and FDA approvals lags other drug classes. Tufts Center for the Study of Drug Development Impact Report 2012; 14: RS3216.